<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, March 25, 2019 (HealthDay News) — Patients with poor cognitive function have significantly lower levels of Alzheimer disease-related biomarkers in the vitreous humor, according to a study published March 8 in the Journal of Alzheimer’s Disease<\/i>.<\/p>\n
Lauren M. Wright, M.D., from the Boston University School of Medicine, and colleagues analyzed vitreous humor samples from 80 eyes of 80 individuals to quantify levels of beta amyloid-\u03b2 (A\u03b240<\/sub>, A\u03b242<\/sub>), phosphorylated tau (pTau), and total tau (tTau). Serum was also used to determine apolipoprotein E (APOE) status. Participants underwent testing with the Mini-Mental State Exam (MMSE).<\/p>\n The researchers found that lower MMSE scores were significantly associated with lower levels of vitreous A\u03b240<\/sub> (P = 0.015), A\u03b242<\/sub> (P = 0.0066), and tTau (P = 0.0085). There was no association between these biomarkers and any preexisting eye conditions. There was a trend toward an association between the presence of the \u03b54 allele and the \u03b52 allele with reduced A\u03b240<\/sub> level (P = 0.053) and increased p-Tau level (P = 0.056), respectively.<\/p>\n “Results suggest ocular proteins may have a role for early dementia detection in individuals at-risk for Alzheimer disease,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n